Synlico
Synlico Inc.
Synlico Inc. is an AI-powered drug discovery company dedicated to transforming traditional approaches in oncology through the development of engineered T cell therapies tailored to combat solid tumors. By harnessing advanced computational techniques, Synlico leads a paradigm shift in understanding and addressing the complexities of cellular behavior in the tumor microenvironment.
Products & Team
CausalCell AI
CausalCell AI is a computational technology platform that utilizes single-cell bioinformatics combined with machine learning and causal discovery methodologies. This advanced platform provides invaluable insights into the tumor microenvironment, enhancing the ability to develop targeted T cell therapies.
CausalCell AI fundamentally addresses the issues of low drug potency and the disparity between preclinical and clinical outcomes by offering precise insights into the intricate interactions within tumors, thereby paving the way for more effective therapeutic interventions.
Synlico addresses significant challenges faced in drug development processes, including the heterogeneity of disease environments, the inefficiency of traditional screening methods, and the need for more reliable models correlating preclinical results with clinical efficacy.